Research Topics
| Xiongpeng ZhuSummaryCountry: China Publications
|
Detail Information
Publications
[Construction of recombinant adenovirus vector containing human survivin gene and its expression in dendritic cells]Xiong Peng Zhu
Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou 350001, China
Zhongguo Shi Yan Xue Ye Xue Za Zhi 14:791-4. 2006..It is concluded that the recombinant adenovirus vector containing human survivin was constructed successfully, which may provide preliminary laboratory evidence for anti-leukemia immunotherapy...
[Induction of anti-lymphoma cytotoxic T cell effect by dendritic cells transfected with recombinant adenovirus vectors carrying survivin gene]Xiong Peng Zhu
Department of Hematology, The Affiliated Quanzhou First Hospital, Fujian Medical University, Quanzhou 362000, China
Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:591-3. 2007..It is concluded that DCs transfected with Ad-survivin can induce CTL response in vitro against lymphoma cells...
In vitro inducing effect of dendritic cells cotransfected with survivin and granulocyte-macrophage colony-stimulating factor on cytotoxic T cell to kill leukemic cellsXiong Peng Zhu
Department of Hematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, Fujiang 362000, China
Chin Med J (Engl) 121:2180-4. 2008....
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlightsXiongpeng Zhu
Department of Hematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, 362000, China
J Hematol Oncol 3:17. 2010..This review also summarizes the updates of the clinical trials on novel agents including voreloxin, AS1413, behenoylara-C, ARRY520, ribavirin, AZD1152, AZD6244, and terameprocol (EM-1421) from the 2009 ASH annual meeting...
